Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided…
Continue Reading-
Oncoinvent Advances Radspherin[®] to Second Dose Level in Ongoing Phase 1 Clinical Trial
FRI, SEP 04, 2020 09:19 CET Safety review of first dose-level cohort allows progression to…
Continue Reading -
Abliva receives positive FDA feedback on its KL1333 development plan
Abliva AB (Nasdaq Stockholm: ABLI) today announced that it has received positive feedback from the…
Continue Reading -
Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss
PIPE-505 is the first small molecule developed specifically for the treatment of sensorineural hearing loss…
Continue Reading -
Gesynta raises SEK 190 million in round led by Hadean Ventures to accelerate development of first-in-class mPGES-1 inhibitor GS-248 for systemic sclerosis
July 7, 2020, Stockholm Gesynta Pharma AB (‘Gesynta’ or ‘The Company’) a clinical-stage company…
Continue Reading -
€1.9M EU funding takes Nelli® available for all epilepsy patients
Neuro Event Labs (NEL) will use €1.9M EU Horizon 2020 grant to become the standard…
Continue Reading -
Abliva completes the directed issue of MSEK 20 to Hadean Ventures
On April 22, 2020, the Board of Directors of Abliva AB (publ) (“Abliva” or the…
Continue Reading -
Oncoinvent Announces Dosing of First Patient with Radspherin® in a Second Phase 1 Clinical Trial
Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from…
Continue Reading -
Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial
Press Release 02.2020: Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosis…
Continue Reading
